Archer-Daniels-Midland (ADM) has significantly outperformed the S&P 500 over the past year and year-to-date, driven by strong oilseed processing fundamentals, robust demand for soybean meal, and increased earnings expectations. Despite a recent slight dip from its 52-week high, ADM shares have demonstrated a solid bullish trend. The company, a major player in agricultural processing, is benefiting from expanding into value-added nutrition and sustainable agriculture trends, although it has slightly underperformed rival Bunge Global SA.

This article highlights three defense stocks—Lockheed Martin (LMT), Northrop Grumman (NOC), and RTX (RTX)—that are attractive buys in June due to their substantial backlogs and favorable sector outlook. Lockheed Martin benefits from a $194 billion backlog and new multi-year agreements, Northrop Grumman has seen a positive inflection with its B-21 program, and RTX offers diversified growth with a $271 billion backlog and raised 2026 guidance. The article emphasizes that with significant government allocation to munitions, execution of existing contracts will be key for these companies.

ON Semiconductor (ON) has significantly outperformed the broader technology sector, with its shares gaining 102.4% over the past three months compared to the State Street Technology Select Sector SPDR ETF's (XLK) 34.1% rise. The company specializes in intelligent power and sensing technologies for automotive, industrial, and cloud applications, and its strong performance is attributed to increasing demand for silicon carbide chips in EVs and renewed optimism in AI infrastructure. Analysts maintain a "Moderate Buy" rating for ON, highlighting its positive prospects amidst easing interest rates.

Vistra (NYSE:VST) is highlighted as a significant player in the AI data center energy sector, attracting investment from billionaires due to increasing power demands. The company benefits from its considerable generation capacity, including nuclear power, and its ability to provide bridge power to data centers, making it a flexible and essential utility. Despite its strong position, the article suggests other AI stocks might offer higher returns in a shorter timeframe.

Johnson & Johnson announced that its multiple myeloma drug Talvey, when combined with Halozyme-partnered Darzalex Faspro, significantly reduced the risk of death by up to 53% in a late-stage trial. This bispecific T-cell engager therapy showed superior efficacy compared to standard treatments for multiple myeloma patients. The positive trial results indicate a substantial improvement in patient outcomes, potentially offering a new treatment standard.

Wells Fargo's Chief Equity Strategist Ohsung Kwon warns that surging AI token costs and the end of "token-maxxing" subsidies pose a significant risk to hyperscaler stocks like Microsoft and Meta Platforms. These companies are already facing increasing capital expenditures for AI infrastructure, forcing them to pass higher costs to customers. Despite strong financial performance, both Microsoft and Meta have seen their stock prices struggle as investors question the long-term returns on these massive AI-related investments.

PHINIA (NYSE:PHIN) has been upgraded to a "strong-buy" rating by KeyCorp, following similar upgrades from Zacks Research, Weiss Ratings, and Wall Street Zen. The company reported strong quarterly earnings, surpassing analyst estimates, with revenue up 10.3% year-over-year. Insider transactions show recent stock sales by company VPs, while institutional investors and hedge funds largely increased their holdings in PHINIA.

State Street Corp significantly increased its holdings in Altria Group, Inc. (NYSE:MO) by 1.6% in the fourth quarter, bringing its total position to 72,830,531 shares valued at approximately $4.28 billion. Other hedge funds also adjusted their stakes, with several analysts offering varied price targets and ratings on the stock. Altria Group reported strong quarterly earnings and announced an upcoming quarterly dividend of $1.06 per share.

State Street Corp increased its stake in CVS Health Corporation by 2.1% in the fourth quarter, purchasing an additional 1,245,457 shares and bringing its total ownership to over 60 million shares valued at $4.78 billion. Other hedge funds also adjusted their holdings in CVS, while the company has seen positive sentiment regarding its expansion into GLP-1 weight-loss drugs, AI integration, and mental health services. CVS Health reported strong Q1 earnings, with EPS of $2.57 against an estimate of $2.21, and its stock recently hit a 52-week high, although some insider selling has occurred.

State Street Corp has increased its stake in Deere & Company by 0.9% in the fourth quarter, now owning 10,485,949 shares valued at $4.9 billion. Other institutional investors like Norges Bank and Capital World Investors also significantly increased their holdings in the industrial products company. Deere & Company recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $1.62 per share.